-
公开(公告)号：US20250034184A1
公开(公告)日：2025-01-30
申请号：US18684284
申请日：2022-08-17
Applicant: Emory University , Villanova University
Inventor： William Wuest , Kevin Minbiole
Abstract: This disclosure relates to quaternary phosphonium compounds having lipophilic groups. In certain embodiments, this disclosure relates to quaternary phosphonium compounds having chemical formula as reported herein. In certain embodiments, this disclosure relates to compositions and devices comprising or coated with quaternary phosphonium compounds disclosed herein. In certain embodiments, this disclosure relates to preventing or treating a microbial infection or cancer using quaternary phosphonium compounds disclosed herein.
-
公开(公告)号：US20240300987A1
公开(公告)日：2024-09-12
申请号：US18569323
申请日：2022-01-24
Inventor： Byoung Heon KANG , So-Yeon KIM , Nam Gu YOON
IPC: C07F9/6561 , A61K31/66 , A61K31/665 , A61K31/675 , A61P35/00 , C07F9/54 , C07F9/572 , C07F9/655
CPC classification number: C07F9/6561 , A61K31/66 , A61K31/665 , A61K31/675 , A61P35/00 , C07F9/5442 , C07F9/5456 , C07F9/572 , C07F9/65522
Abstract: The present application provides a compound that inhibits TRAP1 or a pharmaceutically acceptable salt thereof. In this case, the compound or the pharmaceutically acceptable salt thereof can inhibit the binding between TRAP1 and the client protein. In addition, the present application provides: a pharmaceutical composition for the treatment of cancer or ocular disease comprising a compound that inhibits TRAP1 or a pharmaceutically acceptable salt thereof; and use thereof.
-
3.发明公开公开(公告)号：US20240226001A1
公开(公告)日：2024-07-11
申请号：US18142017
申请日：2023-05-01
Applicant: Mitotech S.A.
Inventor： Anton Dmitrievich PETROV , Maxim Vladimirovich SKULACHEV , Vladim Neronovich TASHLITSKY , Elena Mirovna KARGER , Lawrence T. FRIEDHOFF
IPC: A61K9/00 , A61K31/352 , A61K31/36 , A61K31/473 , A61K31/4741 , A61K31/66 , A61P27/02 , C07D311/82 , C09B11/24 , C09B57/00 , C09B69/00 , C11D3/00
CPC classification number: A61K9/0051 , A61K31/352 , A61K31/36 , A61K31/473 , A61K31/4741 , A61K31/66 , A61P27/02 , C07D311/82 , C09B11/24 , C09B57/00 , C09B69/001 , C11D3/0078
Abstract: The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior to the application of lenses or other matrix on the eye surface. After such matrix is positioned on the eye, MTC is translocated from the lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.
-
4.发明公开公开(公告)号：US20240082147A1
公开(公告)日：2024-03-14
申请号：US18238940
申请日：2023-08-28
Applicant: Laboratory Skin Care, Inc.
Inventor： Tetsuro Ogawa , Akira Yamamoto
IPC: A61K9/00 , A61K8/02 , A61K8/24 , A61K8/368 , A61K9/14 , A61K9/16 , A61K31/05 , A61K31/216 , A61K31/23 , A61K31/60 , A61K31/66 , A61K47/02 , A61Q19/00
CPC classification number: A61K9/0014 , A61K8/0279 , A61K8/24 , A61K8/368 , A61K9/143 , A61K9/1611 , A61K31/05 , A61K31/216 , A61K31/23 , A61K31/60 , A61K31/66 , A61K47/02 , A61Q19/008 , A61K2800/56 , Y10S977/773 , Y10S977/906
Abstract: Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.
-
5.发明公开公开(公告)号：US20240050598A1
公开(公告)日：2024-02-15
申请号：US18475470
申请日：2023-09-27
Applicant: Jubilant Draximage inc.
Inventor： Umamaheshwar M. Prasad , Harmik Sohi , Rahul Hasija , Dinesh Kumar , Kamal S. Mehta , Raj Vijaya Kuniyil Kulangara , Ashutosh Agarwal , Dharam Vir
CPC classification number: A61K51/0478 , A61K9/19 , A61K31/66 , A61K51/025
Abstract: The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.
-
Patent Agency Ranking
公开(公告)号：US11857516B2
公开(公告)日：2024-01-02
申请号：US16485416
申请日：2018-02-12
Applicant: Neuromagen Pharma, Ltd.
Inventor： Esther Priel
IPC: A61K31/09 , A61P15/08 , A61K31/137 , A61K31/4025 , A61K31/4545 , A61K31/5377 , A61K31/66
CPC classification number: A61K31/09 , A61K31/137 , A61K31/4025 , A61K31/4545 , A61K31/5377 , A61K31/66 , A61P15/08
Abstract: The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and/or conditions related to fertility and preserving same and conditions related to same. In some aspects, the compounds and or compositions as herein described promote, improve, recover or restore fertility in a subject in need thereof, including in male and/or female subjects. Such methods/uses include promoting, enhancing or improving fertility-associated cell or tissue yield as part of an in vitro fertilization protocol.
-
公开(公告)号：US11814402B2
公开(公告)日：2023-11-14
申请号：US16960967
申请日：2019-02-15
Applicant: Stellenbosch University , University of Cape Town
Inventor： Angelique Blanckenberg , Annick Van Niekerk , Selwyn Frank Mapolie , Sharon Prince
CPC classification number: C07F15/006 , A61K31/66 , A61P35/00
Abstract: This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R1 is phenyl substituted with two occurrences of isopropyl, R2 is Cl, and R3 is independently one or more substituents selected from —O(CH2)2O(CH2)2OH, —O(CH2)2O(CH2)2O(CH2)2OH, —O(CH2)2OH, and —O(CH2)2O(CH2)2OCH3.
-
8.发明公开公开(公告)号：US20230357377A1
公开(公告)日：2023-11-09
申请号：US18339147
申请日：2023-06-21
Applicant: OSSIFI-MAB LLC
Inventor： Debra L. Ellies
IPC: C07K16/22 , A61K38/18 , A61K39/395 , A61K31/66 , A61K31/7088 , A61L27/12 , A61K31/713 , A61K38/17 , A61K31/59 , A61K45/06 , A61L27/54 , A61P19/08
CPC classification number: C07K16/22 , A61K38/1875 , A61K39/3955 , A61K31/66 , A61K31/7088 , A61K39/395 , A61L27/12 , A61K31/713 , A61K38/1709 , A61K31/59 , A61K45/06 , A61L27/54 , C07K2317/55 , C07K2317/76 , C07K2317/24 , A61P19/08 , A61L2300/256 , A61L2300/432 , A61L2430/02
Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
-
公开(公告)号：US11786597B2
公开(公告)日：2023-10-17
申请号：US16448335
申请日：2019-06-21
Applicant: The Regents of the University of California , Triad National Security, LLC , Arizona Board of Regents
Inventor： Michael Zakrewsky , Samir Mitragotri , David T. Fox , Andrew Koppisch , Rico Del Sesto , Katherine Lovejoy
IPC: A01N3/00 , A61K31/215 , A01N37/12 , A01N37/44 , A61K31/24 , A01N25/00 , A61K47/24 , A61K9/00 , A61K47/12 , A01N33/12 , A01N43/36 , A61K31/047 , A61K31/545 , A61K31/66
CPC classification number: A61K47/24 , A01N33/12 , A01N43/36 , A61K9/0014 , A61K31/047 , A61K31/545 , A61K31/66 , A61K47/12 , A01N43/36 , A01N41/06 , A01N33/12 , A01N37/02 , A01N37/04 , A01N37/06 , A01N41/06 , A01N47/28 , A01N49/00
Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
-
10.发明公开公开(公告)号：US20230226086A1
公开(公告)日：2023-07-20
申请号：US18123569
申请日：2023-03-20
Applicant: OSSIFI-MAB LLC
Inventor： Debra L. Ellies
Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating ofa Sost antagonist are also disclosed, as it a method ofincreasing bone density by administering to a mammalian patient a therapeutic amount ofa Sost antagonist together with an antiresorptive drug.
-
-
-
-
-
-
-
-
-
Search Results
3127
records
(took 0.041 seconds)
